{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:10:27Z","timestamp":1759457427253,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1053\/j.ajkd.2004.06.002","type":"journal-article","created":{"date-parts":[[2006,8,31]],"date-time":"2006-08-31T17:13:34Z","timestamp":1157044414000},"page":"369-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypertension"],"prefix":"10.1053","volume":"44","author":[{"given":"David G.","family":"Warnock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Textor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2004.06.002_BIB1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (Complete Version)","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2004.06.002_BIB2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","author":"Abosaif","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB3","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB5","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patient with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB9","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archinte.1995.00430100105012","article-title":"Long-term effects of antihypertensive agents on proteinuria and renal function","volume":"155","author":"Maki","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0895-7061(02)03017-0","article-title":"Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients","volume":"15","author":"Fogari","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB12","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.jhh.1001320","article-title":"Is aldosterone the missing link in refractory hypertension? Aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity","volume":"16","author":"Lim","year":"2002","journal-title":"J Hum Hypertens"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB16","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB17","series-title":"Therapy in Nephrology and Hypertension","first-page":"599","article-title":"Renovascular hypertension and ischemic nephropathy","author":"Textor","year":"2003"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB18","series-title":"Comprehensive Clinical Nephrology","first-page":"41.1","article-title":"Renovascular hypertension","author":"Textor","year":"2000"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0025-6196(11)64210-9","article-title":"Outcomes of atherosclerotic renal artery stenosis managed without revascularization","volume":"75","author":"Chabova","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/qjmed\/92.3.159","article-title":"Management of renovascular disease","volume":"92","author":"Isles","year":"1999","journal-title":"Q J Med"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB21","first-page":"182","article-title":"Multicenter Palmaz stent renal artery stenosis revascularization registry report","volume":"55","author":"Dorros","year":"2002","journal-title":"Catheter and Cardiovasc Interv"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00045415-199907000-00012","article-title":"Primary aldosteronism","volume":"7","author":"Young","year":"1999","journal-title":"Cardiol Rev"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0889-8529(05)70283-8","article-title":"Pheochromocytoma and primary aldosteronism","volume":"26","author":"Young","year":"1997","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma","volume":"287","author":"Lenders","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB27","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","article-title":"Resistant hypertension","volume":"39","author":"Taler","year":"2002","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2004.06.002_BIB28","series-title":"The Kidney and Hypertension","first-page":"139","article-title":"Hypertensive urgencies","author":"Elliott","year":"2004"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638604007383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638604007383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:29:05Z","timestamp":1759454945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638604007383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0272638604007383"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2004.06.002","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2004,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2004.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}